caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Hudson named Brandicourt’s successor as Sanofi’s CEO

atopic dermatitis and asthma therapy Dupixent (dupilumab) and Ablynx’ rare blood disorder product Cablivi (caplacizumab).

Sanofi exits R&D pact with Alnylam on rare disease

Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).
Sanofi extends growth spurt thanks to Genzyme, Dupixent

from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP), which made its debut in Germany in October.
Sanofi gets US okay for $270,000 blood disorder drug Cablivi

The US approval – which comes a few months after Cablivi (caplacizumab) was cleared in the EU – if for the use of Cablivi in combination with plasma exchange and immunosuppressive therapy in
As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
Dupixent helps put Sanofi back on growth track

Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Deal Watch January 2018

bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Novo Nordisk target Ablynx reshuffles its board

lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Detecting Alzheimer’s ahead of a cure: A focus on promising new research...
Can you survive without the blue dot?: Or has the digital world has replaced our brain...